Brought to you by 
Antibody developer KaloBios nets $65.1mm in IPO
01 Mar 2013
Executive Summary
KaloBios Pharmaceuticals Inc. (monoclonal antibodies) has netted $65.1mm through its initial public offering of 8.8mm shares at $8, a steep haircut from the $12-14 range the company was planning on last month (it had also expected to sell just 3.85mm shares). The final IPO terms are closer to what KaloBios had initially set in early January: 8.25mm shares at $8.9.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Antibody developer KaloBios nets $65.1mm in IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice